SelectScience Cancer Research Summit 2023 taking place November 14
Explore the latest developments in cancer research with fellow scientists, manufacturers, and regulatory experts
26 Oct 2023
Join SelectScience® for the virtual Cancer Research Summit 2023 on November 14 to connect with fellow scientists and experts in the field.
Now in its third year, this highly anticipated online event provides a unique platform for the global scientific community engaged in cancer research. It unites researchers, technology innovators and manufacturers, fostering connections and facilitating the exchange of invaluable insights within the field of cancer research. Join the discussion through live Q&A sessions, video interviews, interactive resource booths, and unique networking opportunities for attendees.
Register now to secure your spot and gain access to this interactive platform, featuring presentations and peer-to-peer discussions on topics such as translational research, predictive molecular pathology, artificial intelligence, liquid biopsy, organoids, cancer screening strategies, proteomic profiling, chemotherapy, prognostic cancer biomarkers, immunology, spatial biology, and much more.
Featured speakers include:
Akanksha Khare, M.S.
Senior Scientist, R&D, Agilent Technologies
Akanksha Khare is an advanced R&D scientist in the Genomics Division at Agilent Technologies. She is the lead scientist who has worked on the development, verification, and validation studies for the recent launch of the SureSelect Cancer CGP assay.
Dr. Christophe Deben
Professor of Tumor Biology and Organoids, University of Antwerp
Dr. Deben serves as the Head of the Tumoroid Screening Lab at the University of Antwerp and focuses his cancer research on harnessing cutting-edge technologies to advance 3D cancer modeling and automate drug screening assays.
Dr. Valerie Sloane Jones, PhD
Director, Marketing & Technical Support, RayBiotech, Inc.
Dr. Jones is a Marketing Director and skilled innovation scientist at RayBiotech. She specializes in proteomic research for precision and personalized medicine.
Guido Baechler
CEO, Mainz Biomed
Mainz BioMed offers accessible diagnostic solutions for patients worldwide, specializing in the development of straightforward products designed to detect the early stages of prevalent life-threatening conditions, including colorectal and pancreatic cancers.
Samer Sansil
Core Facility Manager, Moffitt Cancer Center
Samer Sansil works on drug quantitation of novel and standard chemotherapy agents in pre-clinical and early phase human clinical trials in the Cancer Pharmacokinetics & Pharmacodynamics Core at Moffitt Cancer Center.
How the online event works:
Register in advance to secure your entry details and stay updated on the agenda. Bookmark key presentations and add them to your calendar so you don’t miss them. On the day of the event, simply enter the virtual lobby (pictured below) and start exploring!
